Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13768117 | 0.80 | USP2 (0.33) | L3MBTL1LMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL13764332 | 0.79 | GAA (0.31) | L3MBTL1LMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL85557 | 0.79 | NPSR1 (0.35) | L3MBTL1LMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL3220299 | 0.75 | KMT2A (0.45) | L3MBTL1LMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL92825 | 0.73 | CHRNB4 (0.35) | GAAPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL14615842 | 0.72 | CA2 (0.50) | HTTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL5498552 | 0.70 | CA2 (0.48) | HTTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL24367859 | 0.68 | HTR2A (0.33) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL21885778 | 0.68 | KDM4E (0.34) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5633224 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3159345-A1 | INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014145095-A1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-7563785-B2 | Quetiapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | L3MBTL1 4315/4885LMNA 2421/4885HTT 4450/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | L3MBTL1 4486/4885LMNA 2502/4885HTT 4248/4885 |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | GABRA5, HCRTR2, HCRTR1 | L3MBTL1 4536/4885LMNA 1382/4885HTT 1956/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | L3MBTL1 4486/4885LMNA 2502/4885HTT 4248/4885 |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | L3MBTL1 689/4885LMNA 195/4885HTT 944/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | L3MBTL1 4055/4885LMNA 2072/4885HTT 4085/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | L3MBTL1 4486/4885LMNA 2502/4885HTT 4248/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | L3MBTL1 4055/4885LMNA 2072/4885HTT 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.